Copyright West LLC. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna Announces Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)
Single-dose Data from Ongoing PHYOX Phase 1 Trial, Presented at ASN Kidney Week, Show Normalization or Near-normalization of Urinary Oxalate Levels in a Majority of Participants Reductions in Urinary Oxalate, Combined with Favorable Safety/Tolerability Profile, Lay Groundwork for Planned DCR-PHXC...
View HTML
Toggle Summary Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases
- Collaboration provides opportunity to build on Alexion’s more than two decades of complement leadership with expansion into RNAi-based therapies using Dicerna’s GalXC™ technology - - Agreement provides Alexion with exclusive worldwide licenses as well as development and commercial rights for two...
View HTML
Toggle Summary Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary...
View HTML
Toggle Summary Dicerna to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in...
View HTML
Toggle Summary Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the pricing of its underwritten registered public offering of 7,680,492 shares of its common...
View HTML
Toggle Summary Dicerna Announces Proposed Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the commencement of a proposed underwritten registered public offering of 6,150,000 shares of...
View HTML
Toggle Summary Dicerna Announces Proof of Concept for DCR-PHXC in the Treatment of Primary Hyperoxaluria
Initial 6-Week Data in PHYOX Phase 1 Trial Show Significant and Sustained Reduction in Urinary Oxalate Levels Following Single-Dose Administration in Adults with PH1 and PH2 A Detailed Data Readout of the PHYOX Trial is Anticipated in Q4 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep....
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in...
View HTML
Toggle Summary Dicerna Strengthens Board of Directors with Two New Appointments
Industry Veterans J. Kevin Buchi and Cynthia Smith Add Key Industry and Commercial Operations Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today...
View HTML
Toggle Summary Dicerna Reports Second Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the...
View HTML